CN104686501B - Preservative agent compositionss - Google Patents
Preservative agent compositionss Download PDFInfo
- Publication number
- CN104686501B CN104686501B CN201510060953.1A CN201510060953A CN104686501B CN 104686501 B CN104686501 B CN 104686501B CN 201510060953 A CN201510060953 A CN 201510060953A CN 104686501 B CN104686501 B CN 104686501B
- Authority
- CN
- China
- Prior art keywords
- preservative agent
- cytoprotective
- acid
- inhibitor
- product formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003755 preservative agent Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 230000001120 cytoprotective effect Effects 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 239000000872 buffer Substances 0.000 claims abstract description 21
- 239000013522 chelant Substances 0.000 claims abstract description 16
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940009662 edetate Drugs 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960000458 allantoin Drugs 0.000 claims abstract description 3
- 229920000669 heparin Polymers 0.000 claims abstract description 3
- 150000003891 oxalate salts Chemical class 0.000 claims abstract description 3
- 150000002917 oxazolidines Chemical class 0.000 claims abstract description 3
- 239000012530 fluid Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000539 dimer Substances 0.000 claims description 2
- HXMWJLVXIHYART-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide;hydrochloride Chemical compound [OH-].[Na+].Cl.OC(=O)CC(O)(C(O)=O)CC(O)=O HXMWJLVXIHYART-UHFFFAOYSA-M 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 7
- 239000003513 alkali Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 20
- 239000012472 biological sample Substances 0.000 abstract description 14
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- GUPRKDXXJJAUDS-UHFFFAOYSA-M Cl.[OH-].[Na+].NCC(=O)O Chemical compound Cl.[OH-].[Na+].NCC(=O)O GUPRKDXXJJAUDS-UHFFFAOYSA-M 0.000 abstract 1
- CZDSWGSBWBDBQV-UHFFFAOYSA-N acetic acid;pentan-1-amine Chemical compound CC(O)=O.CCCCCN CZDSWGSBWBDBQV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 description 12
- 239000000523 sample Substances 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 235000013877 carbamide Nutrition 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 229940048820 edetates Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GZAGDUDNLKUBSZ-UHFFFAOYSA-N 1-bromo-2-nitropropane Chemical compound BrCC(C)[N+]([O-])=O GZAGDUDNLKUBSZ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- -1 dihydroxymethyl Chemical group 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Preservative agent compositionss, including：A) one or more cytoprotective；B) one or more inhibitor；C) one or more chelate stabilizer；D) one or more acid-base buffer；Wherein, one or more in allantoin, 5,5 dimethyl hydantion, oxazolidines of described cytoprotective；Described inhibitor is selected from N acetic acid azomethines, one or more of N (3 acetic acid amylamine)；One or more in edetate, oxalates, heparinate, citrate of described chelate stabilizer；Described acid-base buffer agent can be glycine sodium hydroxide hydrochloride buffer.Preservative agent compositionss of the present invention can long-storage products preparation or biological sample at normal temperatures, the preservative agent system is without free aldehyde material, safety and reliability, is conducive to keeping product formulation, biological sample amplifying nucleic acid integrity, it is ensured that the accuracy of nucleic acid material detection.
Description
Technical field
It is the present invention relates to be used for the compositionss of preservative agent, especially a kind of for preserving product formulation or biological sample not
The compositionss of the preservative agent of aldehyde-containing type material.
Background technology
To prevent or delaying certain material to go bad during long-term preservation, generally add preservative agent wherein so that thing
Matter material in certain storage time does not go bad, and this preservative agent has no effect on its detection or uses.
The material for adding preservative agent is needed to include biological sample, various products preparation than more typical example.In these necks
In domain, the class preservative agent more often used in prior art is aldehydes preservative agent, and its main species includes：
(1) aldehyde material itself, such as formaldehyde, acetaldehyde, glutaraldehyde etc.；
(2) formaldehyde donor and formaldehyde derivatives, bromo- 5 nitro -1 of such as 5-, bromo- 2 nitropropane -1 of 3- dioxs, 2-, 3-
Glycol, N- (methylol)-N- (dihydroxymethyl -1,3- titanium dioxide -2,5- imidazoles -4)-N '-(methylol) urea, 4,4 '-dimethyl
Oxazolidine, imidazolidinyl urea, double imidazolidinyl urea etc..This kind of preservative agent has stronger sterilization and anticorrosion characteristic, therefore has good
Good preservation effect.
But, with immunocytochemistry and nucleic acid chemistry progress, it has been found that these preservative agent systems contain trip
From aldehyde material, especially free formaldehyde, there is stronger crosslinking, destruction with for protein and nucleic acid material,
People are directly resulted in biological sample of the contact with such preservative agent or product formulation, generation anaphylaxiss, toxicity are anti-
Should, or even have carcinogenic risk.This kind of additive is used in biological sample field, as protein, nucleic acid material are destroyed, directly
Connecing causes for such material, it is impossible to detect or have a strong impact on the legitimate reading of detection, causes testing result to deviate truth
And the conclusion of science cannot be given.
Therefore, still in the urgent need to a kind of preservative agent compositionss without free aldehyde material be used for preserve product formulation or
Biological sample.
The content of the invention
The present invention seeks to overcome the deficiencies in the prior art, there is provided a kind of for preserving product formulation or biological sample not
The compositionss of the preservative agent containing free aldehyde material, this preservative agent compositionss are contained to overcome in existing preservative agent system
The shortcoming of free aldehyde material.
For achieving the above object, the present invention is adopted the following technical scheme that.
The preservative agent compositionss are included：
A) one or more cytoprotective；
B) one or more inhibitor；
C) one or more chelate stabilizer；
D) one or more acid-base buffer.
The cytoprotective is selected from N- (2,5- dioxo -4- imidazoline piperidinyls) carbamide (allantoin), 5,5- dimethyl
Glycolylurea, (one or more in carbamide), oxazolidines of carbonyl diamine urea.
The one kind or many of the inhibitor in the Schiff's base and its dimer, trimer of fatty race's azomethine base
Kind.
The Schiff's base of described fatty race's azomethine base is selected from N- acetic acid azomethine or N- (3- acetic acid-amylamine) azomethine
In one or more.
The one kind or many of the chelate stabilizer in edetate, oxalates, heparinate, citrate
Kind；
The acid-base buffer is Glycine-NaOH-hydrochloride buffer, citric acid-sodium hydroxide-hydrochloride buffer
One kind in liquid, tris-HCI buffer, the final pH value of system is in 3.0～8.0 scopes.
Cytoprotective is 1 with the mol ratio of inhibitor:0.1～1:4.0.Preferably, cytoprotective and inhibitor
Mol ratio is 1:0.1～1:3.0.Further preferably, cytoprotective and the mol ratio of inhibitor are 1:1.
Depending on the addition of the cytoprotective is for the volume of process biological sample or product formulation according to needed for, preferably
, when handling liquid samples or product formulation, add by 0.001～5.0g/ml fluid samples or product formulation.
The addition of the inhibitor, calculates addition by mol ratio of the cytoprotective with inhibitor.
Depending on the addition of the chelate stabilizer is according to the required volume for processing biological sample or product formulation product, compared with
Good, when handling liquid samples or preparation, add by 1.0～4.0mg/ml fluid samples or product formulation.The amount of preferably using is
2.2mg/ml fluid samples or product formulation.
Depending on the addition of the acid-base buffer is according to the required volume for processing biological sample or product formulation, preferably
, when handling liquid samples or product formulation, add by the percentage by volume for accounting for fluid sample or product formulation 1～5%.
Preferred technical scheme is：Chelate stabilizer edetate, by 2.2mg/ml fluid samples or product system
Agent is added, i.e., every milliliters of liquid sample or product formulation add 2.2mg edetates；Cytoprotective and inhibitor
Mol ratio is 1:1；Cytoprotective is 0.005g/ml fluid samples or preparation, i.e., every milliliters of liquid sample or product formulation add
Plus the cytoprotective of 0.005g；Inhibitor presses cytoprotective addition corresponding with the mol ratio of inhibitor；Acid-base buffer
Addition be the 3% of fluid sample or volumes of formulation percent.
Compared to prior art, the beneficial effects of the present invention is：
Preservative agent compositionss of the present invention can long-storage products preparation or biological sample at normal temperatures, the preservative agent
System reduces allergy when human contact is added with the fluid sample of this preservative agent, biological sample without free aldehyde material
Reaction, toxic reaction, reduce the potential carcinogenic risk of preservative agent, are conducive to the nucleic acid in holding product formulation, biological sample
Integrity, it is ensured that nucleic acid material detection accuracy, science, be given closer to real testing result.
Description of the drawings
C13 spectrum detection collection of illustrative plates of the Fig. 1 for preservative agent compositionss described in the embodiment of the present invention 1；
C13 spectrum detection collection of illustrative plates of the Fig. 2 for preservative agent compositionss described in the embodiment of the present invention 2.
Specific embodiment
Below, with reference to accompanying drawing 1, accompanying drawing 2 and specific embodiment, the present invention is described further：
Embodiment 1：For processing blood sample
This is one embodiment that preservative agent compositionss of the present invention are used for biological product.
When preparing the preservative agent of process 10ml blood samples, first by 300 microlitres of calculating of volume of addition preservative agent, according to
It is preferred that chelate stabilizer EDTA-K3Concentration 2.2mg/ml blood, in configuration additive needed for calculating, the concentration of anticoagulant is
73mg/ml, if configuration 100ml preservative agents, then need to add EDTA-K37.3g.Other additives press following criterion calculation, carefully
Born of the same parents' protective agent is 0.005g/ml blood by concentration；Cytoprotective is 1 with the mol ratio of inhibitor:1.
The final configuration proportion of each adding ingredient of configuration 100ml preservative agents is as follows：
| EDTA-K3 | 7.3g |
| 5,5- dimethyl hydantion | 16.7g |
| N- acetic acid azomethines | 11.4g |
Said mixture is settled to into 100ml finally, pH7.2 tris-HCI buffers are final to obtain
Preservative agent finished product.
As shown in figure 1, after C13 spectrum detections are carried out to above-mentioned preservative agent finished product, it is seen that without destruction nucleic acid in additive
The free aldehyde material of integrity；C13 spectrum testing results show：In 82ppm positions without absworption peak, show that preservative agent system is not contained
Free aldehyde material.
Embodiment 2：For processing cosmetic liquid body preparation
This is one embodiment that preservative agent compositionss of the present invention are used for non-biological specimen.
When preparing the preservative agent of process 10ml liquid preparations, first by 300 microlitres of the volume of addition preservative agent, according to preferred
Chelate stabilizer EDTA-Na2.2H2The concentration 2.2mg/ml cosmetic liquid body preparation of O, anticoagulant in configuration preservative agent needed for calculating
Concentration be 73mg/ml, if configuration 100ml preservative agents, then need add EDTA-Na2.2H2O 7.3g.Other additives are pressed
Following criterion calculation, cytoprotective are 0.002g/ml cosmetic liquid body preparations by concentration；Cytoprotective is rubbed with inhibitor
You are than being 1:1.
Preferably, when preparing 100ml preservative agent finished products, each adding ingredient configuration proportion is as follows：
Said mixture is settled to into 100ml pH7.2 tris-HCI buffers finally, it is final to obtain
Preservative agent finished product.
As shown in Fig. 2 after C13 spectrum detections are carried out to above-mentioned preservative agent finished product, it is seen that without destruction nucleic acid in additive
The free aldehyde material of integrity.C13 spectrum testing results show：In 82ppm positions without absworption peak, show that preservative agent system is not contained
Free aldehyde material.
Embodiment 3
The present embodiment is improved on the basis of embodiment 1.
Preservative agent compositionss are included：
A) one or more cytoprotective；
B) one or more inhibitor；
C) one or more chelate stabilizer；
D) one or more acid-base buffer；
E) one or more antioxidant；
F) antibiotic of one or more Antithemolytic streptococcus；
Wherein, chelate stabilizer edetate, is added by 2.2mg/ml fluid samples or product formulation, i.e., per milli
Rise fluid sample or product formulation addition 2.2mg edetates；Cytoprotective is 1 with the mol ratio of inhibitor:1；
Cytoprotective is the thin of 0.005g/ml fluid samples or preparation, i.e., every milliliters of liquid sample or product formulation addition 0.005g
Born of the same parents' protective agent；Inhibitor presses cytoprotective addition corresponding with the mol ratio of inhibitor；The addition of acid-base buffer is liquid
The 3% of body sample or volumes of formulation fraction.
The Main Function of antioxidant is hemocyte damaged membrane caused by the beta oxidation for slowing down fatty acid, this kind of antioxygen
The mechanism of agent is mainly quenching activity oxygen.The present invention adopts Vitamin E or Butylated hydroxyanisole (BHA).Being used as oil BHA more
Fat antioxidant, to thermally-stabilised.Except antioxygen it is outside the pale of civilization, also stronger antimicrbial power.Addition can suppress golden Portugal when being 150mg/kg
Grape coccus, staphylococcus aureuses pollution can pollute product, and be unfavorable for the preservation of product.
Preferably, the antibiotic of Antithemolytic streptococcus selects amoxicillin.Some collected blood sample persons suffer from certain
A little illness, blood are contained within Hemolytic streptococcuss, and this can cause haemolysis and cause blood products to go bad, and such as the density of hemocyte becomes
Change etc..The antibiotic of addition Antithemolytic streptococcus contributes to preserving product.By weight, consumption is 0.03%～0.04%.
It will be apparent to those skilled in the art that technical scheme that can be as described above and design, make other various
It is corresponding to change and deformation, and all these change and deformation should all belong to the protection domain of the claims in the present invention
Within.
Claims (8)
1. preservative agent compositionss, it is characterised in that include,
A) one or more cytoprotective；
B) one or more inhibitor；
C) one or more chelate stabilizer；
D) one or more acid-base buffer,
Characterized in that,
One or more in allantoin, 5,5- dimethyl hydantion, oxazolidines of described cytoprotective；
One or more in the Schiff's base and its dimer, trimer of fatty race's azomethine base of described inhibitor；
One or more in edetate, oxalates, heparinate, citrate of described chelate stabilizer；
Described acid-base buffer be Glycine-NaOH-hydrochloride buffer, citric acid-sodium hydroxide-hydrochloride buffer,
One kind in tris-HCI buffer, the final pH value range of system are 3.0～8.0.
2. preservative agent compositionss according to claim 1, it is characterised in that the Schiff of described fatty race's azomethine base
One or more in N- acetic acid azomethine or N- (3- acetic acid-amylamine) azomethine of alkali.
3. preservative agent compositionss according to any one of claim 1-2, it is characterised in that cytoprotective and inhibitor
Mol ratio is 1:0.1～1:4.0.
4. preservative agent compositionss according to claim 3, it is characterised in that cytoprotective with the mol ratio of inhibitor is
1:0.1～1:3.0.
5. preservative agent compositionss according to claim 3, it is characterised in that cytoprotective with the mol ratio of inhibitor is
1:1。
6. preservative agent compositionss according to any one of claim 1-2, it is characterised in that
Described cytoprotective adds 0.001 by fluid sample or product formulation in handling liquid samples or product formulation
The dosage addition of～5.0g/ml cytoprotectives；
Described chelate stabilizer adds 1.0～4.0mg/ by fluid sample or product formulation in handling liquid samples or preparation
The dosage addition of ml chelate stabilizers；
Described acid-base buffer, in handling liquid samples or product formulation, by accounting for fluid sample or product formulation 1～5%
Percentage by volume is added.
7. preservative agent compositionss according to claim 6, it is characterised in that described chelate stabilizer, in treatment liquid sample
When product or preparation, by the dosage addition of fluid sample or product formulation addition 2.2mg/ml chelate stabilizers.
8. preservative agent compositionss according to claim 7, it is characterised in that the using dosage of cytoprotective is per milliliter
Fluid sample or product formulation add the cytoprotective of 0.005g；The addition of acid-base buffer is fluid sample or preparation body
The 3% of product percent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060953.1A CN104686501B (en) | 2015-02-05 | 2015-02-05 | Preservative agent compositionss |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510060953.1A CN104686501B (en) | 2015-02-05 | 2015-02-05 | Preservative agent compositionss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104686501A CN104686501A (en) | 2015-06-10 |
| CN104686501B true CN104686501B (en) | 2017-04-05 |
Family
ID=53334399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510060953.1A Expired - Fee Related CN104686501B (en) | 2015-02-05 | 2015-02-05 | Preservative agent compositionss |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104686501B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023203451A1 (en) * | 2022-04-20 | 2023-10-26 | Translational Health Science And Technology Institute | Universal microbial sample transport medium for genomic and metagenomic studies |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106719598B (en) * | 2016-11-28 | 2020-07-24 | 张家港市德仁科教仪器设备有限公司 | Composition and environment-friendly specimen preservation solution prepared from same |
| CN107325818B (en) * | 2017-06-28 | 2019-11-15 | 奥斯汀生命科学技术公司 | Composite antioxidant, anti-oxidant sampling apparatus and purposes |
| CN107509722B (en) * | 2017-08-30 | 2020-11-10 | 迈克生物股份有限公司 | Specimen preservation solution |
| CN109090104A (en) * | 2018-09-27 | 2018-12-28 | 广州新诚生物科技有限公司 | Save liquid and its preparation method and application |
| CN109566599A (en) * | 2018-12-25 | 2019-04-05 | 南京健邦锦源医疗仪器有限公司 | A kind of exfoliated cell preservative fluid |
| CN109997843A (en) * | 2019-04-15 | 2019-07-12 | 无锡芯超生物科技有限公司 | A kind of circulation dissociative DNA and haemocyte save medium |
| CN111165470A (en) * | 2020-01-21 | 2020-05-19 | 广州维帝医疗技术有限公司 | Urine preserving fluid and preparation method and application thereof |
| CN112244025A (en) * | 2020-11-27 | 2021-01-22 | 上海创宏生物科技有限公司 | Sterile treatment agent for macromolecular protein and/or nucleic acid and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538752A (en) * | 2005-04-12 | 2008-11-06 | クレオ コスメティック アンド ファーマスーティカルカンパニー エルエルシー | Compositions and methods for preserving corneal tissue in vitro |
| CN101965829B (en) * | 2010-09-30 | 2012-11-28 | 中国人民解放军第三军医大学野战外科研究所 | Method for cryopreserving erythrocytes |
| CN102726366B (en) * | 2011-04-07 | 2014-06-04 | 中国人民解放军第二军医大学 | Organ preservation solution and method for preparing same |
-
2015
- 2015-02-05 CN CN201510060953.1A patent/CN104686501B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023203451A1 (en) * | 2022-04-20 | 2023-10-26 | Translational Health Science And Technology Institute | Universal microbial sample transport medium for genomic and metagenomic studies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104686501A (en) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104686501B (en) | Preservative agent compositionss | |
| Spreer et al. | Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone | |
| Dain et al. | The occurrence of histamine and tyramine in rumen ingesta of experimentally over-fed sheep | |
| El-Sayed et al. | Evaluation of the in vitro and in vivo inhibitory effect of thymoquinone on piroplasm parasites | |
| RU2574011C2 (en) | Lyophilised preparation of botulinum toxin | |
| CN107083382B (en) | A kind of blood preseration agent and its application for protecting dissociative DNA | |
| Rizk et al. | Evaluation of the inhibitory effect of N-acetyl-L-cysteine on Babesia and Theileria parasites | |
| El-Deeb et al. | Clinico-biochemical Investigation of Paratuberculosis of Dromedary Camels in Saudi Arabia: Proinflammatory Cytokines, Acute Phase Proteins and Oxidative Stress Biomarkers. | |
| Young et al. | Chloramphenicol with fluid and electrolyte therapy cures terminally ill green tree frogs (Litoria caerulea) with chytridiomycosis | |
| El-Mandrawy et al. | Hematological, biochemical and oxidative stress studies of lumpy skin disease virus infection in cattle | |
| Deller | Iron59 absorption measurements by whole-body counting: Studies in alcoholic cirrhosis, hemochromatosis, and pancreatitis | |
| Simola et al. | Pathologic findings and toxin identification in cyanobacterial (Nodularia spumigena) intoxication in a dog | |
| Söyüt et al. | The impact of heavy metals on the activity of carbonic anhydrase from rainbow trout (Oncorhynchus mykiss) kidney | |
| Harlow et al. | Inhibition of fructan‐fermenting equine faecal bacteria and Streptococcus bovis by hops (Humulus lupulus L.) β‐acid | |
| CN111378719A (en) | Reagent compositions and methods for preserving nucleic acid integrity in human saliva | |
| Gökçe et al. | Alterations in some haematological and biochemical parameters in cattle suffering from foot-and-mouth disease | |
| Umamaheswari et al. | Chronic amoxicillin exposure affects Labeo rohita: assessment of hematological, ionic compounds, biochemical, and enzymological activities | |
| Igbokwe et al. | Effect of acute Trypanosoma vivax infection on cattle erythrocyte glutathione and susceptibility to in vitro peroxidation | |
| Deljou et al. | Clinical, laboratory and pathological findings in sub-acute monensin intoxication in goats | |
| Osman | Clinical, haematological and therapeutic studies on babesiosis in Arabian horses in the Qassim region, central of Saudi Arabia | |
| Carbis et al. | A biochemical profile for predicting the chronic exposure of sheep to Microscystis aeruginosa, an hepatotoxic species of blue-green alga | |
| CN204897890U (en) | Novel blood sample is collected device | |
| Brandão et al. | Platelet aggregation studies in acute experimental canine ehrlichiosis | |
| Pal et al. | www. ijarbs. com Coden: IJARQG (USA) | |
| Edem et al. | Innate cellular immunity in newly diagnosed pulmonary tuberculosis patients and during chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20161221 Address after: 510260 Guangdong, Guangzhou, Xingang West Road, No. 135, a large compound in the park in the park on the middle of the science and Technology Park, No. A, block, No. 1201, room 1202, 1212 Applicant after: GUANGZHO WEIDI MEDICAL TECHNOLOGY CO.,LTD. Address before: 510000 Guangdong, Xingang, No. 135 West Guangzhou Road, science and technology building, block A, floor, building 12 Applicant before: GUANGZHOU SUN-SHING BIOTECH Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170405 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |